We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life
Read MoreHide Full Article
For Immediate Release
Chicago, IL –June 10, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Mastercard (MA - Free Report) , Disney (DIS - Free Report) , Abbott (ABT - Free Report) , Workday (WDAY - Free Report) and Sun Life (SLF - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Mastercard, Disney and Abbott Labs
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard, Disney and Abbott. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Mastercard’s shares have increased +28.9% in the past year, outperforming the Zacks Financial Transaction Services industry’s rally of +17.3%. The Zacks analyst thinks the company is poised for growth, given its solid market position, ongoing expansion and digital initiatives, and opportunities from the shift toward electronic payments. Its numerous acquisitions have aided revenue growth.
For several quarters now, the company has been gaining from higher switched transactions, increase in cross-border volumes and gross dollar volumes, and gains from acquisitions, partly offset by an increase in rebates and incentives. However, escalating costs will weigh on margins.
Also, in order to gain customers and more business, Mastercard has been incurring quite a high level of cost in terms of rebates and incentives, which remains a concern. However, its strong balance sheet enables business investment, thereby driving growth.
Shares of Disney have gained +25.5% year to date, outperforming the Zacks Media Conglomerates industry’s gain of +22.3% during the same period. The company’s top line in the near term is expected to benefit from the solid performance of Avengers: Endgame. Currently, the film holds the record for the fastest earning $1 billion film globally, beating Avengers: Infinity War’s record.
The Zacks analyst thinks Disney is likely to benefit from the strong adoption of ESPN+. Further, Disney+ (to be launched this November), which will be supported by Disney and Fox’s content, may give tough competition to Netflix and Amazon.
But increasing investments in ESPN+ and Disney+ and losses from streaming technology services are expected to hurt margins. Higher programming costs at ESPN due to increase in contractual rates for a few sports programs may keep profits under pressure.
Abbott’s shares have gained +26.6% over the past year, significantly outperforming the Zacks Medical Products industry, which has increased +2.2% over the same period. Abbott exited first quarter 2019 with better-than-expected earnings and revenues figures.
The Zacks analyst likes the company’s strong and consistent performance by the company’s EPD and Medical Devices segments on an organic basis. The company has been hogging the limelight within Diabetic Care on the growth it has enjoyed with FreeStyle Libre. Within Structural Heart, worldwide strong uptake of MitraClip has improved further following the FDA approval of its upgraded version.
This apart, synergies from Alere consolidation in the form of revenues from Rapid Diagnostics have been driving growth. On the flip side, sluggish Rhythm Management arm in the United States is denting growth. Increasing currency headwinds has somewhat dented Abbott’s international performance in the past-reported quarter.
Other noteworthy reports we are featuring today include Workday and Sun Life.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life
For Immediate Release
Chicago, IL –June 10, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Mastercard (MA - Free Report) , Disney (DIS - Free Report) , Abbott (ABT - Free Report) , Workday (WDAY - Free Report) and Sun Life (SLF - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Mastercard, Disney and Abbott Labs
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard, Disney and Abbott. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Mastercard’s shares have increased +28.9% in the past year, outperforming the Zacks Financial Transaction Services industry’s rally of +17.3%. The Zacks analyst thinks the company is poised for growth, given its solid market position, ongoing expansion and digital initiatives, and opportunities from the shift toward electronic payments. Its numerous acquisitions have aided revenue growth.
For several quarters now, the company has been gaining from higher switched transactions, increase in cross-border volumes and gross dollar volumes, and gains from acquisitions, partly offset by an increase in rebates and incentives. However, escalating costs will weigh on margins.
Also, in order to gain customers and more business, Mastercard has been incurring quite a high level of cost in terms of rebates and incentives, which remains a concern. However, its strong balance sheet enables business investment, thereby driving growth.
(You can read the full research report on Mastercard here >>>).
Shares of Disney have gained +25.5% year to date, outperforming the Zacks Media Conglomerates industry’s gain of +22.3% during the same period. The company’s top line in the near term is expected to benefit from the solid performance of Avengers: Endgame. Currently, the film holds the record for the fastest earning $1 billion film globally, beating Avengers: Infinity War’s record.
The Zacks analyst thinks Disney is likely to benefit from the strong adoption of ESPN+. Further, Disney+ (to be launched this November), which will be supported by Disney and Fox’s content, may give tough competition to Netflix and Amazon.
But increasing investments in ESPN+ and Disney+ and losses from streaming technology services are expected to hurt margins. Higher programming costs at ESPN due to increase in contractual rates for a few sports programs may keep profits under pressure.
(You can read the full research report on Disney here >>>).
Abbott’s shares have gained +26.6% over the past year, significantly outperforming the Zacks Medical Products industry, which has increased +2.2% over the same period. Abbott exited first quarter 2019 with better-than-expected earnings and revenues figures.
The Zacks analyst likes the company’s strong and consistent performance by the company’s EPD and Medical Devices segments on an organic basis. The company has been hogging the limelight within Diabetic Care on the growth it has enjoyed with FreeStyle Libre. Within Structural Heart, worldwide strong uptake of MitraClip has improved further following the FDA approval of its upgraded version.
This apart, synergies from Alere consolidation in the form of revenues from Rapid Diagnostics have been driving growth. On the flip side, sluggish Rhythm Management arm in the United States is denting growth. Increasing currency headwinds has somewhat dented Abbott’s international performance in the past-reported quarter.
(You can read the full research report on Abbott here >>>).
Other noteworthy reports we are featuring today include Workday and Sun Life.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.